FDA Committee Recommends Approval of Epidiolex
Incredible strides were made on April 19th when the advisory committee of the Food and Drug Administration (FDA) recommended the approval of Epidiolex, the first prescription cannabidiol medicine, as a treatment for certain severe types of epilepsy. Cannabidiol, also known as CBD, is derived from cannabis and has been receiving a lot of attention recently due to its medicinal properties. This approval represents an advancement for hemp seed oil products like ours, which are CBD extracts.
Epidiolex is a pharmaceutical that has been approved for the treatment of Lennox-Gastaut syndrome and Dravet syndrome in patients older than two. These extremely rare forms of epilepsy are incredibly debilitating, causing hundreds of seizures in sufferers every day. Given orally in syrup form, this drug has gone through rigorous testing to ensure its purity. The secret to the effectiveness of this prescription lies in CBD.
CBD is currently being studied extensively due to the incredible results it has shown for a variety of ailments. Three studies on these two seizure disorders have shown it to be an effective treatment for epilepsy with minimal risks. Research is also being conducted into CBD’s effectiveness in treating anxiety, autism, arthritis, inflammation and autoimmune disorders.